VIR-2218 + VIR-3434 (Combination)
Chronic Hepatitis Delta (HDV)
Phase 3Recruiting (ECLIPSE Registrational Program)
Key Facts
Indication
Chronic Hepatitis Delta (HDV)
Phase
Phase 3
Status
Recruiting (ECLIPSE Registrational Program)
Company
About Vir Biotechnology
Vir Biotechnology is a public biotech company developing antibody-based therapies for infectious diseases and cancer. Its strategy is built on deep immunology expertise and two core technology platforms: a next-generation antibody platform for infectious diseases and the PRO-XTEN® protease-releasable masking technology for oncology. The company's most advanced program is in Phase 3 for chronic hepatitis delta, and it has demonstrated capability in rapidly advancing candidates, as seen with its COVID-19 and Ebola programs. Vir is led by an experienced management team and board with a track record of drug development and commercialization.
View full company profile